



Miltenyi Biotec

# TheraSorb® – Ig omni 5 adsorber

Effective removal of IgG, IgM, IgA, and IgE

The TheraSorb – Ig omni 5 adsorber belongs to Miltenyi Biotec's new generation of adsorbers containing recombinant antibody fragments as ligands.

- Low risk of reaction to foreign proteins<sup>1</sup>
- Removal of free lambda and kappa light chains<sup>1</sup>
- Designed for five treatments<sup>1</sup>

► [miltenyibiotec.com](http://miltenyibiotec.com)



## TheraSorb – Ig omni 5 adsorber

The TheraSorb – Ig omni 5 adsorber has been carefully designed for the specific removal of human immunoglobulins containing lambda and kappa chains, including IgG (subclasses IgG1–IgG4), IgA, IgM, IgE, and immune complexes as well as free lambda and kappa light chains from human plasma in extracorporeal immunoadsorption procedures, as the plasma flows through the column.

### Areas of application

The TheraSorb – Ig omni 5 adsorber is intended to be used for immunoadsorption treatment of diseases in which pathogenic immunoglobulins, lambda or kappa light chains, and immune complexes, contribute to the onset of the disease or its progression. A positive benefit-risk ratio has been shown by clinical trials or case series in conjunction with other modes of treatment in the following exemplary indications:

- idiopathic dilated cardiomyopathy NYHA II – IV<sup>2</sup>
- ABO blood group incompatible living donor kidney transplantation<sup>3,4</sup>
- acquired hemophilia with an inhibitor titer to factor VIII of more than 5 Bethesda Units<sup>5</sup>
- pulmonary arterial hypertension NYHA II – III<sup>6</sup>
- thrombangiitis obliterans (Buerger's disease)<sup>7</sup>
- myasthenia gravis/myasthenic crisis<sup>8</sup>
- focal segmental glomerulosclerosis, recurrent and idiopathic form<sup>9</sup>
- severe systemic lupus erythematosus<sup>10</sup>
- antiphospholipid syndrome in pregnancy<sup>11</sup>
- severe atopic dermatitis<sup>12</sup>
- antibody-mediated rejection after kidney transplantation<sup>13</sup>
- long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)<sup>14</sup>


This adsorber is specific for the removal of human immunoglobulin and free antibody light chains from the patient's plasma. Over 96% of circulating IgG can be removed in the course of six immunoadsorption sessions using the TheraSorb – Ig omni 5 adsorber (fig. 1)<sup>15</sup>. At the same time, also IgA and IgM titers are lowered by more than 93% and 88%, respectively (fig. 1)<sup>15</sup>.

### Product specifications

Shelf life	36 months*
Sepharose volume	100 mL
Immunological target	IgG, IgM, IgA, and IgE, free lambda and kappa light chains

\*Please note: Adsorber must be stored between 2 and 8 °C.

Product	Order no.
TheraSorb – Ig omni 5 adsorber kit	330-000-965
LIFE 21® – Ig omni 5 disposables set large	330-000-821
LIFE 21 – Ig omni 5 disposables set small	330-000-822



**Figure 1:** Reduction of serum immunoglobulins during immunoadsorption treatments (median of 5.5–6) with TheraSorb – Ig flex adsorbers, TheraSorb – Ig omni 5 adsorbers (both from Miltenyi Biotec), and a product from another manufacturer. TheraSorb – Ig flex is a predecessor product of TheraSorb – Ig omni 5. Reduction refers to the immunoglobulin value prior to treatment. Values are means  $\pm$  SEM. Reproduced from Atherosclerosis Supplements, 40, Speer *et al.*, Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion, 68–72, 2019, with permission from Elsevier.

## References

1. Internal data
2. Dandel, M. *et al.* (2012) Eur. J. Heart Fail. 14: 1374–1388.
3. Teschner, S. *et al.* (2012) J. Clin. Apher. 27: 51–60.
4. Becker, L.E. *et al.* (2015) Transplantation 99: 2364–2371.
5. Zeitler, H. *et al.* (2012) Transfusion Med. Hemother. 39: 264–270.
6. Nagel, C. *et al.* (2017) Respiration 94: 263–271.
7. Baumann, G. *et al.* (2011) Clin. Res. Cardiol. 100: 683–690.
8. Zeitler, H. *et al.* (2006) Artif. Organs 30: 597–605.
9. Allard, L. *et al.* (2018) Nephrol. Dial. Transplant. 33: 954–963.
10. Kronbichler, A. *et al.* (2016) Autoimmunity Rev. 15: 38–49.
11. Bontadi, A. *et al.* (2012) J. Clin. Apher. 27: 200–204.
12. Reich, K. *et al.* (2016) J. Allergy Clin. Immunol. 137: 1882–1884.
13. Koller, H. *et al.* Transpl. Int. 17: 177–181.
14. Stein, E. *et al.* (2024) Lancet Reg. Health Eur. 49: 101161.
15. Speer, C. *et al.* (2019) Atheroscler. Suppl. 40: 68–72.



Miltenyi Biotec B.V. & Co. KG | Phone +49 2204 8306-0 | Fax +49 2204 85197 | macsde@miltenyi.com | [www.miltenyibiotec.com](http://www.miltenyibiotec.com)

Miltenyi Biotec provides products and services worldwide. Visit [www.miltenyibiotec.com/local](http://www.miltenyibiotec.com/local) to find your nearest Miltenyi Biotec contact.

All products of the TheraSorb product line are designed, manufactured and tested under a quality system certified to ISO 13485 and are available as CE-marked medical devices in the EU. In the US, select TheraSorb products are available for investigational use under an approved Investigational Device Exemption (IDE) or FDA approval. LIFE 21, the Miltenyi Biotec logo, and TheraSorb are registered trademarks or trademarks of Miltenyi Biotec B.V. and Co. KG and/or its affiliates in various countries worldwide. Copyright © 2025 Miltenyi Biotec and/or its affiliates. All rights reserved.